Matsui H, Takizawa J, Kojima K, Tauchi T, et al. Response to comments on "Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan". Int J Hematol 2026 Jul 14. doi: 10.1007/s12185-026-04253.
PMID: 42446593